


REMARKS

Claims 1-15 and 21-24 are pending in this application. The Examiner has required restriction to one of 18 groups. In response to such restriction, Applicants provisionally elect Examiner's Group I (claims 1-12, 21, and 24) drawn to compounds and pharmaceutical formulations of Formula (Ia). Applicants expressly reserve the right to file divisional applications directed to the subject matter encompassed by the remaining subject matter.

Applicants believe that no fees are due in connection with the filing of this paper other than those specifically authorized herewith. However, should any other fees be deemed necessary to the timely filing of this paper the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392.

Respectfully submitted,



Karen L. Prus
Attorney for Applicants
Registration No. 39,337

Date: April 4, 2007

GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive, P.O. Box 13398
Research Triangle Park, North Carolina 27709
(919) 483-2192